UK, Sweden Test Differing Antibiotic Market Models
But Both Seek Reward Mechanisms That Assure National Antibiotic Supplies
Executive Summary
Sweden and the UK are conducting differing ‘develop and test’ programs to assess so-called ‘pull’ incentives in which an antibiotics innovator will be paid an annual fee in return for an access guarantee for anti-infectives. The projects have drawn keen attention from other countries.
You may also be interested in...
BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.
Global ‘Talent Contest’ Seeks To Spur AMR Innovation
Novo Holdings’ REPAIR Impact Fund has opened a global ‘AMR talent contest’ to groups developing new antimicrobial treatments, offering direct investment as the prize.
Global AMR R&D Hub Launches Dynamic Data Dashboard
The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.
| Table |
|---|